Aaron Berger

Kimball, United States

Aaron Berger is a UNL Extension Educator focused on providing information on forage, range and beef production to producers in the High Plains region.

Featured in: Favicon

nytimes.com Favicon

mdpi.com

qz.com

weforum.org Favicon

nymag.com

startribune.com Favicon

rapidcityjournal.com Favicon

nrcresearchpress.com Favicon

theindependent.com Favicon

sabc.co.za + 48 more

Articles

Strategic supplementation on summer pasture made money in yearling grazing study

1 week ago | starherald.com | Aaron Berger

A three-year experiment at the High Plains Ag Lab was conducted by Karla Wilke and a team of researchers from the University of Nebraska-Lincoln to evaluate the effects of two distillers grains supplementation strategies on yearling cattle performance and producer returns to management. Yearling cattle were grazed on pastures consisting primarily of crested wheatgrass.
Strategic supplementation on summer pasture made money in yearling grazing study

1 week ago | tsln.com | Aaron Berger

A three-year experiment at the High Plains Ag Lab was conducted by Dr. Karla Wilke and a team of researchers from the University of Nebraska-Lincoln to evaluate the effects of two distillers grains supplementation strategies on yearling cattle performance and producer returns to management. Yearling cattle were grazed on pastures consisting primarily of crested wheatgrass.
Assessing Tolerability and Clinical Considerations in Abiraterone Formulation Selection

1 week ago | urologytimes.com | Aaron Berger

Abiraterone Formulation Options and Patient AdherenceThis segment provides detailed information about the 3 main abiraterone acetate formulations available for treating metastatic castration-resistant prostate cancer. The traditional formulation requires 1000 mg daily (four 250-mg tablets) taken on an empty stomach with strict fasting requirements—no food 2 hours before and 1 hour after administration—combined with prednisone 5 mg twice daily.
A 74-Year-Old Man With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

1 week ago | urologytimes.com | Aaron Berger

mCRPC Case PresentationThis segment presents a comprehensive case study of a man aged 74 years diagnosed with mCRPC. The patient’s journey began 4 years ago with high-risk localized prostate cancer, progressing through radical prostatectomy, biochemical recurrence, salvage radiation therapy, and eventually developing bone metastases.
Reflecting on NMIBC Progress: Highlights From AUA 2025 and What’s Ahead

2 weeks ago | urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger

OpinionVideoJune 12, 2025Author(s):,Panelists discuss how recent advancements in NMIBC treatment, including the approval of nadofaragene firadenovec, pembrolizumab, and intravesical therapies like TAR-200, have reshaped care for BCG-unresponsive patients, with promising developments and ongoing trials at AUA 2025 paving the way for more personalized and effective treatment strategies in the future.
Navigating Access Barriers: Resources to Support New Treatment Access

2 weeks ago | urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger

OpinionVideoJune 12, 2025Author(s):,Panelists discuss how leveraging resources such as patient assistance programs, insurance navigators, clinical trial databases, advocacy groups, and oncology support services can help overcome access barriers, ensuring that NMIBC patients receive timely access to novel treatments like nadofaragene firadenovec and pembrolizumab.
Overcoming Challenges in Accessing New Therapies for NMIBC

2 weeks ago | urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger

OpinionVideoJune 12, 2025Author(s):,Panelists discuss how overcoming challenges such as cost, insurance coverage, regulatory hurdles, patient selection, and the need for education is crucial for improving access to novel therapies like nadofaragene firadenovec and pembrolizumab, ultimately enhancing outcomes for NMIBC patients.
Topline Results From Recent NMIBC Trials

3 weeks ago | urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger

Author(s):,Panelists discuss how recent trials, including KEYNOTE-057, QUILT-3.032, and CORE-001, highlight the promising efficacy, durability, and manageable safety profiles of novel treatments like pembrolizumab, nogapendekin alfa inbakicept, and nadofaragene firadenovec, while also exploring the potential of combination therapies and novel intravesical options like TAR-200 and UGN-102 for improving outcomes in non–muscle-invasive bladder cancer (NMIBC).
Exploring Nadofaragene Firadenovec: Ongoing Trials and Study Designs

3 weeks ago | urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger

Author(s):,Panelists discuss how the ongoing ABLE-32 and ABLE-41 trials are exploring the efficacy and safety of nadofaragene firadenovec in different NMIBC patient populations, with ABLE-32 focusing on intermediate-risk patients and ABLE-41 examining real-world effectiveness and safety. The ongoing clinical trials investigating nadofaragene firadenovec include the ABLE-32 and ABLE-41 trials, each focusing on different aspects of its use in treating non-muscle invasive bladder cancer (NMIBC).
Limit Feeding with a Bale Feeder, Bunk and a Bucket

3 weeks ago | m.farms.com | Aaron Berger

By Aaron BergerDrought conditions are challenging producers to be creative as they think about options for maintaining the cowherd through the summer with limited pasture available. Several research studies conducted at the University of Nebraska have shown that cows can be managed effectively utilizing a limit fed ration.